Thursday, May 10, 2018
BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib
* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment